New Heart Failure Drug Struggles To Find Its Footing

–Experts offer insight about Entresto at the ESC. Despite its success in a large and widely praised clinical trial the novel heart failure drug Entresto (sacubitril/valsartan, Novartis) has been struggling to gain a substantial foothold in the marketplace. Now new papers and presentations and commentary from experts at the European Society of Cardiology meeting are...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Heart Failure Policy & Ethics cost effectiveness Entresto LCZ 696 PARADIGM Source Type: blogs